Previous 10 | Next 10 |
CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded today at a new 52-week high of $15.58. So far today approximately 116.5 million shares have been exchanged, as compared to an average 30-day volume of 401,000 shares. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. It...
CymaBay Therapeutics (NASDAQ:CBAY) announced results from the Phase 2, 52-week study of Seladelpar in patients with primary biliary cholangitis (PBC). The company said the mid-stage study examined the efficacy and safety of seladelpar in adults with PBC who were receiving or intolerant to fir...
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the Phase 2, 52-...
CymaBay Therapeutics, Inc. (CBAY) Q4 2021 Earnings Conference Call March 17, 2022 16:30 ET CompanyParticipants Paul Quinlan - General Counsel Sujal Shah - President & Chief Executive Officer Daniel Menold - Vice President of Finance Charles McWherter - Chief Scientific Officer Dennis Kim ...
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q4 2021 Earnings Call Mar 17, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q4 2021 Earnings Call Transcript...
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to it...
CymaBay Therapeutics press release (NASDAQ:CBAY): Q4 GAAP EPS of -$0.34 misses by $0.11. The company had $194.6M in cash, cash equivalents and short-term investments as of December 31, 2021. For further details see: CymaBay Therapeutics GAAP EPS of -$0.34 misses by $0.11
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the...
CymaBay Therapeutics (NASDAQ:CBAY) is scheduled to announce Q4 earnings results on Thursday, March 17th, after market close. The consensus EPS Estimate is -$0.20 (+13.0% Y/Y) and the consensus Revenue Estimate is $7.5M For further details see: CymaBay Therapeutics Q4 2021 Earnings Previ...
NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live au...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...